Recently, seminal studies by Zelenay and colleagues demonstrated that genetic ablation of COX-2 reinforced the antitumor type I immune response and the accumulation of Batf2-dependent CD103+ dendritic cells (DC) in the TIME in a mouse model of BrafV600E melanoma (15, 21). This evidence concerns the gene PTGS2 and melanoma.